Direct factory allocation of high-purity research and therapeutic peptide APIs with full analytical certification, NMR, HR-MS confirmation, and high-performance liquid chromatography analysis.
Atrial Peptide (human ANP / alpha-ANP / Carperitide) represents one of the most critical endocrine regulators of fluid volume, arterial blood pressure, and cardiovascular homeostasis.
Atrial Natriuretic Peptide (ANP) is a 28-amino acid polypeptide hormone endogenous to mammalian cardiac myocytes. Structurally defined by a conserved 17-amino acid cyclic core anchored through a single intramolecular disulfide bridge between Cys7 and Cys23, this cyclic conformation is strictly indispensable for high-affinity docking with Natriuretic Peptide Receptor-A (NPR-A / GC-A). Binding triggers the catalytic conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), setting off a cascade of vasodilation, natriuresis, diuresis, and systemic blood pressure reductions while counterbalancing the renin-angiotensin-aldosterone system (RAAS).
In modern pharmaceutical therapeutics, pharmaceutical-grade recombinant and chemically synthesized atrial peptide analogues—such as Carperitide (recombinant human alpha-ANP), Ularitide (urodilatin, 32-amino acid variant), and related B-type counterparts like Nesiritide—occupy essential therapeutic positions in acute decompensated heart failure (ADHF), cardiorenal syndrome, post-myocardial infarction remodelling prevention, and refractory pulmonary hypertension.
Chemical Challenge in Custom Synthesis: The exact closure of the Cys7-Cys23 ring, avoiding mispaired oligomeric antiparallel dimers and preserving optical integrity during cleavage and deprotection, demands advanced solid-phase peptide synthesis (SPPS) design, selective protecting group pairing (such as Acm/Trt orthogonal strategies), and continuous flow microreactor oxidation.
Thinheal Pharma-Tech leverages nearly two decades of peptide synthesis mastery to overcome the classical degradation pathways of atrial peptides—namely rapid enzymatic degradation by neutral endopeptidase (NEP / Neprilysin, EC 3.4.24.11) and receptor-mediated clearance via NPR-C. Through targeted site-directed chemical modification, terminal capping, lipidation, PEGylation, and unnatural D-amino acid substitution, our custom peptide CDMO division creates ultra-stable, patentable long-acting natriuretic peptide derivatives with prolonged terminal elimination half-lives (t1/2).
Strategic development milestones targeting long-acting delivery vectors, dual incretin-natriuretic conjugations, and green scalable chemical synthesis platforms.
Unmodified native ANP has an ultra-short in vivo half-life of 2 to 5 minutes, restricting historic use to continuous intravenous infusion in critical care. Our chemical roadmap focuses on covalent fatty-diacid side chain conjugation (e.g., C18-diacid, C20-diacid with gamma-Glu-OEG linkers), enabling non-covalent albumin hitchhiking.
Cardiometabolic diseases intersect severe insulin resistance, non-alcoholic steatohepatitis (MASH), and progressive hypertensive cardiomyopathy. Thinheal’s research team pioneers hybrid synthetic architectures integrating GLP-1/GIP glucagon-family pharmacophores directly with cyclic natriuretic peptide rings.
Traditional multi-kilogram solid-phase peptide synthesis consumes vast solvent volumes (DMF, NMP, DCM). Our roadmap establishes proprietary Liquid-Phase / Solid-Phase Hybrid processes utilizing green bio-based dipolar aprotic solvents (such as Cyrene and 2-MeTHF) and automated cleavage precipitation lines.
Connecting molecular pharmacology to high-prevalence cardiorenal indications, accelerating development schedules from hit discovery through commercial drug substance supply.
ANP analogues act as rapid-acting vasodilators that mitigate pulmonary capillary wedge pressure (PCWP) and systemic vascular resistance (SVR) without precipitating reflex inotropic toxicity.
By selectively relaxing preglomerular afferent arterioles while constricting efferent arterioles, synthetic ANP maintains glomerular filtration rate (GFR) and shields vulnerable renal tubules from ischemic damage.
Chronic activation of local cardiac GC-A receptors dampens endothelin-1 signaling, blocks myocyte hypertrophy, and suppresses extracellular matrix collagen deposits during ventricular remodelling.
Inhaled and systemic formulations of synthetic atrial peptide derivatives selectively decrease mean pulmonary arterial pressure (mPAP) with reduced risk of catastrophic peripheral hypotension.
Hangzhou Thinheal Pharma-Tech integrates deep operational automation, localized upstream raw material security, and high-throughput chromatographic purification.
The production of complex cyclic peptides like Atrial Peptide has historically faced international supply bottlenecks due to fluctuating availability of high-purity protected amino acids (Fmoc-Cys(Trt)-OH, Fmoc-Cys(Acm)-OH, pseudoprolines) and specialized coupling reagents. Situated in the heart of China’s life-science cluster in Hangzhou, Thinheal controls a resilient, vertically integrated supply ecosystem.
Our Industry 4.0 Intelligent Synthesis Base deploys automated distributed control systems (DCS) across our multi-ton chemical synthesis lines. Real-time Process Analytical Technology (PAT)—incorporating in-line UV sensors, automated feedback coupling temperature regulators, and process mass spectrometry—ensures each amino acid addition undergoes complete acylation with conversion rates exceeding 99.5%, preventing deletion sequences before cleavage.
We source protected amino acids, Wang/CTC resins, and cleavage reagents from audited domestic primary synthesizers, mitigating geopolitical disruptions and guaranteeing 100% material lot traceability.
High-resolution DAC (Dynamic Axial Compression) chromatography columns up to 1000mm diameter paired with multi-step reverse-phase purification isolate the intact monomer from isomeric impurities and multimers.
Controlled aseptic freeze-drying suites safeguard the physical stability of lyophilized peptide cakes, preventing moisture absorption, deamidation, and aggregation during intercontinental transit.
Structured pricing matrices tailored to biopharmaceutical pipelines—from early academic discovery to commercial-scale validated manufacturing campaigns.
| Procurement Tier | Typical Scale | Purity Threshold | Analytical Package | Turnaround Time | Service Inclusions |
|---|---|---|---|---|---|
| Discovery & Screening | 1 mg – 100 mg | ≥90% to ≥95% | HPLC, ESI-MS, Standard CoA | 10 – 14 Working Days | Salt exchange (TFA to Acetate), lyophilized powder in serum vials |
| Preclinical Tox & Formulation | 1 g – 100 g | ≥98.0% | HPLC, HRMS, Amino Acid Analysis, Karl Fischer water, Residual Solvents | 3 – 4 Weeks | Endotoxin testing (<5 EU/mg), counter-ion quantification, stability advisory |
| IND-Enabling & Clinical Phase I/II | 500 g – 10 kg | ≥99.0% | Full GMP release, 2D NMR, Sequence confirmation, Related substance profile | 6 – 8 Weeks | Batch record documentation, ICH stability testing protocol, Method validation |
| Commercial Multi-Kilogram Supply | 10 kg – 100+ kg | ≥99.5% | Compendial testing (USP/EP standards), Impurity ID, Heavy metals, Bioburden | Scheduled Rolling Supply | DMF Type II filing support, on-site/virtual client quality audits, dedicated QA team |
*Note on Pricing Dynamics: Custom Atrial Peptide pricelists vary according to structural sequence length (e.g., 28-aa native vs. 32-aa Ularitide), chosen counter-ion (Acetate, Chloride, or TFA-free formulation), and specific isotopic labeling (13C, 15N) requirements. Contact our international contract desk for formal RFP quotations within 24 business hours.
Navigating stringent health authority expectations with seamless CMC dossiers, CTD Module 3 authoring, and dedicated regional support offices.
Full conformance with ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients. Every commercial campaign is backed by extensive raw data packages designed to satisfy FDA 21 CFR Part 210/211 and European EudraLex Volume 4 regulations.
We provide comprehensive Active Substance Master Files (ASMF) and US Type II Drug Master Files (DMF). Our regulatory affairs specialists support filing teams directly, addressing health authority questions with validated analytical methods and impurity identification.
Thinheal operates specialized desks covering North America, Western Europe, Japan, and the Asia-Pacific region. Our clients communicate directly with peptide chemists and regulatory advisors fluent in their regional time zones and statutory requirements.
Immediate dispatch and project-scale manufacture of high-affinity therapeutic analogues, metabolic disease APIs, and neuroprotective sequences.
Direct answers to the scientific, analytical, and supply continuity considerations evaluated by technical procurement and pharmaceutical QA specialists.
Thin